# VarmX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/varmx-b-v

- Industry: Biotechnology
- Headquarters: Leiden, Netherlands
- Website: www.varmx.com
- Total disclosed funding: $79M
- Latest round: Series B (May 25, 2023)
- Investors on record: 9

## About

Based in the Netherlands, VarmX B.V. is a biopharmaceutical company focused on developing innovative solutions for restoring blood coagulation in patients on anticoagulant therapies.VarmX B.V. specializes in the development of advanced therapeutic agents for managing bleeding complications in patients using Factor Xa Direct Oral Anticoagulants (FXa-DOACs). The company was founded in 2016 in Leiden, Netherlands. Pieter Reitsma is the founder, and Jeffrey Lawson serves as the CEO. In its journey, VarmX has successfully completed 7 deals and raised a total of EUR 32.00 mn, with the latest funding round being a Series B led by Sound Bioventures. This funding round has provided the capital necessary for further advancements in their product pipeline and market reach.VarmX specializes in the development of VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). This innovative product addresses severe bleeding and mitigates surgical risks for individuals on this class of anticoagulants. VMX-C001 enables rapid treatment of severe hemorrhages, facilitating emergency surgeries with reduced bleeding risks. VarmX's clients include healthcare institutions, surgeons, and medical professionals in Europe and North America, where the need for effective therapeutic interventions for FXa-DOACs is significant.VarmX operates a revenue model centered around partnerships with healthcare providers, enabling the distribution of VMX-C001. The company sells directly to hospitals and clinics, integrating its product into emergency care protocols. Transactions typically involve bulk purchasing agreements, ensuring consistent availability of VMX-C001. Pricing structures are developed based on medical needs and agreements with healthcare entities, highlighting the critical role of the product in life-saving situations.VarmX plans to continue developing new products to enhance its portfolio in the coagulation therapeutics space, although specific release dates have not been disclosed. The company is targeting expansion into additional markets in Europe and North America, aimed at increasing access to its products. The recent funding from MaasInvest will support these initiatives, enabling VarmX to further its product development and geographical expansion efforts.

## Funding rounds

- Series B, May 25, 2023, $34M — EQT Life Sciences, BioGeneration Ventures, Ysios Capital Partners, Lundbeckfond Ventures, Inkef, InnovationQuarter, Libertatis Ergo Holding B.V., European Innovation Council, Sound Bioventures
- Series B, Jul 8, 2020, $36M — EQT Life Sciences, BioGeneration Ventures, Ysios Capital Partners, Lundbeckfond Ventures, Inkef, InnovationQuarter
- Series A, Jul 2, 2018, $8.7M — BioGeneration Ventures, InnovationQuarter
- Seed, Jun 27, 2017 — BioGeneration Ventures, InnovationQuarter

## Investors

- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed, Series A, Series B
- InnovationQuarter (https://capitalatlas.ai/funds/innovationquarter) — Seed, Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series B
- Libertatis Ergo Holding B.V. — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Sound Bioventures (https://capitalatlas.ai/funds/sound-bioventures) — Series B